Abstracts tagged "Psoriatic arthritis"

Abstract Number: 992 • 2017 ACR/ARHP Annual Meeting
The Effect of Anti-TNF Therapy on Work Productivity and Activity Impairment in Patients with Rheumatoid Arthritis, Ankylosing Spondylitis and Psoriatic Arthritis over One Year – Real Life Data from the Czech Biologics Registry Attra
Jakub Zavada¹, Lenka Szczukova², Karel Pavelka³ and Jiri Vencovsky³, ¹Institute of Rheumatology, Prague, Czech Republic, ²Institute of Biostatistics and Analyses. Faculty of Medicine, Masaryk University, Brno, Czech Republic, ³Institute of Rheumatology and Department of Rheumatology, First Faculty of Medicine, Charles University, Prague, Czech Republic
Background/Purpose: The ATTRA registry captures more than 95% of patients with RA, PSA or AS treated with biologics in the Czech Republic (CZ). In CZ,…
Abstract Number: 2800 • 2017 ACR/ARHP Annual Meeting
Long-Term Safety and Efficacy of Biosimilar Infliximab (CT-P13) after Switching from Originator Infliximab: Results from the 26-Week Open Label Extension of a Randomized Norwegian Trial
Guro Løvik Goll¹, Kristin Kaasen Jørgensen², Joe Sexton¹, Inge C Olsen³, Nils Bolstad⁴, Merete Lorentzen⁵, Espen A. Haavardsholm⁶, Cato Mork⁷, Jorgen Jahnsen⁸ and Tore K Kvien⁹, ¹Dept Rheumatology, Diakonhjemmet Hospital, Oslo, Norway, ²Dept Gastroenterology, Akershus University Hospital, Lørenskog, Norway, ³Department of Rheumatology, Diakonhjemmet Hospital, Oslo, Norway, ⁴Department of Medical Biochemistry,, OUS-Radiumhospitalet, Oslo, Norway, ⁵Dept of Dermatology, Rikshospitalet, Oslo, Norway, ⁶Dept. of Rheumatology, Diakonhjemmet Hospital, Oslo, Norway, ⁷Dept of cancer and Molecular medicine, Norwegian University of Science and Technology, Trondheim, Norway, ⁸Dept of Gastroenterology, Akershus University Hospital, Lorenskog, Norway, ⁹Diakonhjemmet Hospital, Oslo, Norway
Background/Purpose: TNF-inhibitors (TNFi) have improved treatment of rheumatoid arthritis (RA), spondyloarthritis (SpA), psoriatic arthritis (PsA) , Crohn’s disease (CD), ulcerative colitis (UC), and chronic plaque…
Abstract Number: 603 • 2017 ACR/ARHP Annual Meeting
Characterization of Clinical Benefits in Subjects Classified As ACR20 Non-Responders at Week 104 of Apremilast Treatment: Subanalysis of 3 Long-Term, Phase III Trials
Philip J Mease¹, Dafna D Gladman², Arthur Kavanaugh³, Priscila Nakasato⁴, Benoit Guerette⁴, Lichen Teng⁴ and Peter Nash⁵, ¹Swedish Medical Center and University of Washington School of Medicine, Seattle, WA, ²Krembil Research Institute, Toronto Western Hospital, Toronto, ON, Canada, ³University of California, San Diego, School of Medicine, La Jolla, CA, ⁴Celgene Corporation, Summit, NJ, ⁵University of Queensland, Brisbane, Australia
Background/Purpose: The PALACE 1, 2, and 3 trials evaluated the efficacy and safety of apremilast (APR) in subjects with active psoriatic arthritis (PsA) despite prior…
Abstract Number: 997 • 2017 ACR/ARHP Annual Meeting
Incidence and Clinical Characteristics of Active Tuberculosis in a Cohort of Patients with Inflammatory Arthritis Treated with TNF-Inhibitors
Ana Maria Gheorghiu¹, Alexandru Garaiman², Alexandra Radu², Alina Soare³, Victoria Arama⁴, Dragos Bumbacea⁵, Rucsandra Dobrota⁶, Raida Oneata⁷, Simona Pintilie², Mihaela Milicescu⁷, Ioan Ancuta⁷, Andrei Martin², Mariana Sasu¹, Claudia Ciofu¹, Liviu Macovei¹, Victor Stoica⁷, Mihai Bojinca⁷ and Carina Mihai⁸, ¹Carol Davila University of Medicine and Pharmacy,Internal Medicine and Rheumatology Department ,,Dr.I.Cantacuzino'' Clinical Hospital, Bucharest, Romania, ²Internal Medicine and Rheumatology, CANTACUZINO HOSPITAL, Carol Davila University of Medicine and Pharmacy, Bucharest, Romania, ³Department of Internal Medicine 3 – Rheumatology and Immunology, Universitätsklinikum Erlangen, Friedrich-Alexander-University Erlangen-Nürnberg (FAU), Erlangen, Germany, ⁴Infectious Diseases 1 Department, Matei Bals National Institute for Infectious Diseases, Carol Davila University of Medicine and Pharmacy, Bucharest, Romania, ⁵Department of Pneumology, Elias Emergency University Hospital, Carol Davila University of Medicine and Pharmacy, Bucharest, Romania, ⁶Department of Rheumatology, Center of Experimental Rheumatology, University Hospital Zurich, Zurich, Switzerland, ⁷Carol Davila University of Medicine and Pharmacy, Internal Medicine and Rheumatology Department, Cantacuzino Clinical Hospital, Bucharest, Romania, ⁸Internal Medicine and Rheumatology Dept., Cantacuzino Clinical Hospital, Carol Davila University of Medicine and Pharmacy, Bucharest, Romania
Background/Purpose: Tuberculosis (TB) is a major concern in patients receiving TNF inhibitors (TNFi). Objectives: To assess the incidence of active TB and the efficacy of…
Abstract Number: 604 • 2017 ACR/ARHP Annual Meeting
Consistent Safety Profile with up to 4 Years of Apremilast Treatment: Analysis of Data from 1,493 Subjects with Psoriatic Arthritis in 3 Large, Phase III, Long-Term Studies
Philip J Mease¹, Dafna D Gladman², Juan J. Gomez-Reino³, Stephen Hall⁴, Arthur Kavanaugh⁵, Eric Lespessailles⁶, Georg Schett⁷, Maria Paris⁸, Lichen Teng⁸ and Jürgen Wollenhaupt⁹, ¹Swedish Medical Center and University of Washington School of Medicine, Seattle, WA, ²Toronto Western Research Institute, Toronto, ON, Canada, ³Hospital Clínico Universitario de Santiago, Santiago de Compostela, Spain, ⁴Monash University, CabriniHealth, Melbourne, Australia, ⁵University of California, San Diego, School of Medicine, La Jolla, CA, ⁶University of Orleans, Orleans, France, ⁷Friedrich Alexander University Erlangen-Nurnberg, Erlangen, Germany, ⁸Celgene Corporation, Summit, NJ, ⁹Schön Klinik Hamburg-Eilbek, Klinik fur Rheumatologie, Hamburg, Germany
Background/Purpose: Apremilast (APR), an oral phosphodiesterase 4 inhibitor, regulates immune activity in psoriatic arthritis (PsA) patients. We evaluated the long-term safety of APR treatment for…
Abstract Number: 1256 • 2017 ACR/ARHP Annual Meeting
Uptake of Influenza and Pneumococcal Vaccination in Inflammatory Arthritis
Kieran Murray¹ and Douglas J. Veale², ¹Rheumatology, Rheumatology Specialist Registrar, Dublin 4, Ireland, ²Rheumatology, St. Vincent's University Hospital, Dublin 4, Ireland
Background/Purpose: Inflammatory arthritides such as RA and PsA increase infection risk. The Centre for Disease Control and Prevention (CDC) recommends vaccination against i. influenza for…
Abstract Number: 10L • 2016 ACR/ARHP Annual Meeting
Efficacy and Safety of Tofacitinib, an Oral Janus Kinase Inhibitor, in Patients with Active Psoriatic Arthritis and an Inadequate Response to Tumor Necrosis Factor Inhibitors: OPAL Beyond, a Randomized, Double Blind, Placebo-Controlled, Phase 3 Trial
Dafna D Gladman¹, William Rigby², Valderilio F Azevedo³, Frank Behrens⁴, Ricardo Blanco⁵, Andrzej Kaszuba⁶, Elizabeth Kudlacz⁷, Cunshan Wang⁷, Sujatha Menon⁷, Thijs Hendrikx⁸ and Keith S Kanik⁷, ¹University of Toronto, Toronto, ON, Canada, ²Rheumatology, Dartmouth-Hitchcock Med Ctr, Lebanon, NH, ³Federal University of Parana and Edumed Health Research Center and Biotech, Curitiba, Brazil, ⁴Johann Wolfgang Goethe University, Frankfurt, Germany, ⁵Rheumatology, Hospital Universitario Marqués de Valdecilla. IDIVAL, Santander, Spain, ⁶Specialstyczne Gabinety Lerkarskie "DERMED", Lodz, Poland, ⁷Pfizer Inc, Groton, CT, ⁸Pfizer Inc, Collegeville, PA

Background/Purpose: Tofacitinib is an oral Janus kinase inhibitor under investigation for treatment of PsA. In this first study of tofacitinib in patients (pts) with active…
Abstract Number: 90 • 2016 ACR/ARHP Annual Meeting
Impacts of Anti-TNF Treatment on Improvement in Work Place and Household Productivity in Patients with Psoriatic Arthritis
Omer Karadag¹, Ediz Dalkilic², Ahmet Mesut Onat³, Orhan Kucuksahin⁴, Timucin Kasifoglu⁵, Bunyamin Kisacik⁶, Omer Nuri Pamuk⁷, Neslihan Yilmaz⁸, Suleyman Serdar Koca⁹, Veli Yazisiz¹⁰, Pinar Talu Ocakci¹¹, Mehmet Sayarlioglu¹², Ender Terzioglu¹³, Sukran Erten^14,15, Mustafa Ferhat Oksuz¹⁶ and Umut Kalyoncu¹, ¹Rheumatology, Hacettepe University Faculty of Medicine, Ankara, Turkey, ²Department of Rhematology, Uludag University Faculty of Medicine, Bursa, Turkey, ³Department Of Internal Medicine, Division of Rheumatology, Gaziantep University, Gaziantep University,Division of Rheumatology, Gaziantep, Turkey, ⁴Rheumatology, Yildirim Beyazit University Faculty of Medicine, Ankara, Turkey, ⁵Rheumatology, Eskisehir Osmangazi University Faculty of Medicine, Eskişehir, Turkey, ⁶Rheumatology Department, Gaziantep University School of Medicine, Gaziantep, Turkey, ⁷Rheumatology, Trakya University Faculty of Medicine, Edirne, Turkey, ⁸Department of Rheumatology, Bilim University Faculty of Medicine, Istanbul, Turkey, ⁹Department of Rheumatology Faculty of Medicine Firat University, Elazig, Turkey, ¹⁰Rheumatology, Akdeniz University Faculty of Medicine, Antalya, Turkey, ¹¹Rheumatology, İzmir University Faculty of Medicine, izmir, Turkey, ¹²Rheumatology, Ondokuz Mayis University Faculty of Medicine, Samsun, Turkey, ¹³Division of Rheumatology, Akdeniz University Faculty of Medicine, Antalya, Turkey, ¹⁴Rheumatology, Ataturk Training and Research Hospital, Ankara, Turkey, ¹⁵Rheumatology, Yildirim Beyazit University Faculty Of Medicine, Ankara, Turkey, ¹⁶Rheumatology, Uludag University Faculty of Medicine, Bursa, Turkey
Background/Purpose: Psoriatic arthritis (PsA) is a unique inflammatory arthritis that affects the skin, nails, and the joints. Most of the patients consider PsA to have…
Abstract Number: 1688 • 2016 ACR/ARHP Annual Meeting
Ixekizumab Provides Sustained Improvement up to 52 Weeks of Disease Activity As Assessed By Composite Measure Scores in Biologic Disease-Modifying Antirheumatic Drug-Naive Patients with Active Psoriatic Arthritis
Laura C. Coates¹, M. Elaine Husni², Catherine L. Shuler³, Hilde Carlier³, Chen-Yen Lin³, Jiani Mou³, Chin H. Lee³ and Philip J Mease⁴, ¹University of Leeds, Leeds, United Kingdom, ²Rheumatology, Cleveland Clinic Foundation, Cleveland, OH, ³Eli Lilly and Company, Indianapolis, IN, ⁴Rheumatology Research, Swedish Medical Center and University of Washington, Seattle, WA
Background/Purpose: PsA, a chronic immune-mediated inflammatory disease, can be progressive and destructive, resulting in physical deformities, impaired function, decreased quality of life, and increased mortality.…
Abstract Number: 2169 • 2016 ACR/ARHP Annual Meeting
Presence of Cardiovascular Risk Factors Across Different Inflammatory Joint Disease Entities: Results from a Norwegian, Multi-Centre Project
Grunde Wibetoe¹, Eirik Ikdahl², Silvia Rollefstad², Anne Salberg³, Dag Magnar Soldal⁴, Tore K Kvien⁵, Glenn Haugeberg⁶ and Anne Grete Semb⁷, ¹Rheumatology, Diakonhjemmet Hospital, Oslo, Norway, ²Diakonhjemmet Hospital, Oslo, Norway, ³Hospital for Rheumatic Diseases, Lillehammer, Norway, ⁴Rheumatology, Hospital of Southern Norway, Kristiansand, Norway, ⁵Dept. of Rheumatology, Diakonhjemmet Hospital, Oslo, Norway, ⁶Martina Hansens Hospital, Bærum, Norway, ⁷Preventive Cardio-Rheuma clinic, Dept. of Rheumatology, Diakonhjemmet Hospital, Oslo, Norway
Background/Purpose: EULAR recommendations for cardiovascular disease (CVD) risk management in inflammatory joint diseases (IJD) advocates annual CVD risk assessments to reduce the increased CVD risk.…
Abstract Number: 148 • 2016 ACR/ARHP Annual Meeting
Which Are the Ultrasound Lesions Underlying Dactylitis?
Adrien Nzeusseu Toukap¹, Anne Durnez², Pablo Navarro Guerra³ and Maria Stoenoiu⁴, ¹Department of Rheumatology, Cliniques Universitaires St Luc, Brussels, Belgium, ²Rheumatology department, Cliniques Universitaires Saint-Luc, AZ Jan Portaels, Brussels, Belgium, ³Rheumatology department, Cliniques Universitaires Saint-Luc, Brussels, Belgium, ⁴Service de Rhumatologie, Cliniques Universitaires Saint-Luc,Institut de Recherche Expérimentale et Clinique (IREC), Université catholique de Louvain,, Brussels, Belgium
Background/Purpose: Dactylitis (DACT) is defined as diffuse swelling of the digit and is included in the ASAS criteria for spondyloarthritis. It is a hallmark feature of…
Abstract Number: 1689 • 2016 ACR/ARHP Annual Meeting
Ixekizumab Provides Improvements through 52 Weeks in Physical Function, Quality of Life, and Work Productivity in Biologic Disease-Modifying Antirheumatic Drug-Naive Patients with Active Psoriatic Arthritis
Alice B. Gottlieb¹, M. Elaine Husni², Catherine L. Shuler³, Russel T. Burge³, Chen-Yen Lin³, Chin H. Lee³ and D Gladman⁴, ¹Tufts University School of Medicine, Boston, MA, ²Rheumatology, Cleveland Clinic Foundation, Cleveland, OH, ³Eli Lilly and Company, Indianapolis, IN, ⁴University of Toronto, Toronto, ON, Canada
Background/Purpose: PsA has a negative impact on patients’ quality of life, physical function, and work productivity. Ixekizumab (IXE) is an IgG4 mAb that binds with…
Abstract Number: 2647 • 2016 ACR/ARHP Annual Meeting
Drug Trough Serum Levels Rather Than Antidrug Antibodies Explain Disease Flares in Patients with Rheumatoid Arthritis and Psoriatic Arthritis Treated with TNF Inhibitors in Clinical Remission/Low Disease Activity: A One Year Prospective, Multicenter Study (INMUNOREMAR)
Raimon Sanmarti¹, Jose Inciarte-Mundo¹, Paula Estrada², Maria García Manrique³, Javier Narváez⁴, Antonio Gomez-Centeno³, Jesús Rodríguez-Moreno⁴, Mariona Pascal⁵ and Jordi Yagüe⁵, ¹Rheumatology Department, Hospital Clínic de Barcelona, Barcelona, Spain, ²Rheumatology Department, Hospital Moisès Broggi-Hospital General de L'Hospitalet - Consorci Sanitari Integral, Sant Joan Despí, Spain, ³Rheumatology Department, Hospital Parc Taulí, Sabadell, Spain, ⁴Rheumatology Department, Hospital Universitari de Bellvitge, L’Hospitalet de Llobregat, Spain, ⁵Immunology Department, Hospital Clinic de Barcelona, Barcelona, Spain
Background/Purpose: To determine predictive factors of disease flares, including drug trough serum levels and anti-drug antibodies (Ab) in patients with rheumatoid arthritis (RA) or polyarticular…
Abstract Number: 158 • 2016 ACR/ARHP Annual Meeting
Musculoskeletal Ultrasound Is a Sensitive Imaging Tool for the Assessment of Dynamic Changes of Bone Erosions in Inflammatory Arthritis: A Comparative Analysis with High-Resolution Peripheral Quantitatve Computed Tomography
Stephanie Finzel^1,2, Marina Backhaus³, Sebastian Kraus⁴, Georg Schett⁵ and Reinhard Voll⁶, ¹Department of Rheumatology and Clinical Immunology, Medical Faculty, University Medical Center, University of Freiburg, Freiburg, Germany, ²Department of Internal Medicine III, Rheumatology and Immunology, University of Erlangen, 91054, Germany, ³Rheumatology, Park-Klinik Weissensee, Berlin, Germany, ⁴Dept of Medicine 3, Rheumatology and Clinical Immunology, University of Erlangen-Nuremberg, Erlangen, Germany, ⁵Department of Internal Medicine 3 and Institute for Clinical Immunology, University of Erlangen-Nuremberg, Erlangen, Germany, ⁶Dpt. Rheumatology & Clinical Immunology and Centre for Chronic Immunodeficiency, University Hospital Freiburg, University Medical Center, University of Freiburg, Freiburg, Germany
Background/Purpose: Correct detection of bone erosions is crucial both for diagnosis and for monitoring of treatment response in patients with inflammatory joint diseases. Musculoskeletal ultrasound…
Abstract Number: 1694 • 2016 ACR/ARHP Annual Meeting
Does Treat to Target or Achieving Remission Improve Radiographic Outcome in Psa?
Laura C. Coates^1,2, Elizabeth M.A. Hensor^1,3, Paul Emery⁴, Philip G. Conaghan¹ and Philip S. Helliwell⁵, ¹Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, United Kingdom, ²NIHR Leeds Musculoskeletal Biomedical Research Unit, Leeds, United Kingdom, ³NIHR-Leeds Musculoskeletal Biomedical Research Unit, Leeds, United Kingdom, ⁴NIHR-Leeds Musculoskeletal Biomedical Research Unit and Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, United Kingdom, ⁵NIHR-Leeds Musculoskeletal Biomedical Research Unit, Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, United Kingdom
Background/Purpose: The Tight Control of PsA (TICOPA) study was the first to address treat to target in PsA using the minimal disease activity (MDA)…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].